Skip to main content

3 Result(s)

within Elisabetta Poluzzi Remove this filter Diabetes Remove this filter Metabolic Diseases Remove this filter

and

  1. No Access

    Article

    Signal of potentially protective drug–drug interactions from spontaneous reporting systems: proceed with caution

    Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi… in Acta Diabetologica (2020)

  2. No Access

    Article

    Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system

    To investigate the occurrence of myopathy with oral glucose-lowering drugs (OGLDs) and statins, with a focus on dipeptidyl peptidase-4 inhibitors (DPP4-is).

    Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi… in Acta Diabetologica (2020)

  3. Article

    Open Access

    Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas

    The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitors (DPP4i) are hypoglycaemic agents licensed for the treatment of type 2 diabetes mellitus (T2DM). Although these drugs po...

    Giuseppe Roberto, Francesco Barone-Adesi, Francesco Giorgianni… in BMC Endocrine Disorders (2019)

    Download PDF (1155 KB) View Article